Artiva Biotherapeutics (ARTV) Projected to Post Earnings on Tuesday

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.72) per share for the quarter.

Artiva Biotherapeutics Stock Performance

Shares of ARTV traded down $0.66 during midday trading on Thursday, hitting $5.60. The stock had a trading volume of 83,008 shares, compared to its average volume of 109,003. The company has a 50 day simple moving average of $5.79 and a two-hundred day simple moving average of $9.80. Artiva Biotherapeutics has a twelve month low of $3.37 and a twelve month high of $17.31.

Analyst Upgrades and Downgrades

ARTV has been the subject of a number of recent research reports. HC Wainwright began coverage on Artiva Biotherapeutics in a research report on Monday, December 30th. They set a "buy" rating and a $20.00 price target for the company. Needham & Company LLC reissued a "buy" rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Artiva Biotherapeutics currently has an average rating of "Buy" and a consensus target price of $21.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.